The White House on Tuesday, June 23, denied speculation that President Trump received special access to an experimental weight-loss drug from Eli Lilly.
Senior Deputy Press Secretary Kush Desai denied that any compassionate use application for retatrutide was submitted on behalf of the president.
WH Denies Any Retatrutide Compassionate Use Request for Trump
The denial came after a STAT News story about a 79-year-old man who got the unapproved drug through a rare FDA pathway.
Retatrutide is Eli Lilly’s next-generation obesity treatment, still in clinical trials, which has shown strong results in early testing, with some patients losing significant weight.
The drug works as a triple agonist, targeting hormones that control hunger and metabolism. Many see it as a potential step beyond current options like Ozempic and Zepbound.
STAT reporter Lizzy Lawrence broke the story, forcing the White House to respond via social media.
How the Speculation About Trump Began
She reported that in April, when the patient was 79, officials approved compassionate use for one person.
This program usually helps people with serious or life-threatening conditions try experimental treatments when nothing else works.
Sources told STAT the man had been on another Lilly obesity drug for a year but saw only moderate results.
Lawrence noted that Trump had just turned 80 around that time, and, given the patient’s age and the unusual nature of the request, she asked the White House, the FDA, and HHS whether the patient was the president. She said that until the article was published, she did not get a direct answer at first.
Also Read: Can Omega-3 Prevent Dementia? Hussein Yassine USC Study Explores Benefits of High-Dose DHA
That silence helped the story circulate quickly on social media. By Tuesday afternoon, the exchange between Lawrence and Desai had drawn thousands of views and heated replies.
Desai called the suggestion baseless. In a post on X, he wrote that the application “was not for the President.”
He described Lawrence as an “unserious gossip columnist” and said reporters with standards would not have printed speculation like this.
Lawrence replied that she had asked multiple times and received no direct response until the public denial.
Desai shot back that the White House should not have to knock down every rumor before it appears in print. He asked if she planned to question millions of other Americans in that age group too.
Viral Report Sparks Debate Over Transparency and Presidential Health
The back-and-forth turned a niche medical story into a political flashpoint as supporters of the president praised the quick denial and accused the press of chasing gossip.
On the other hand, critics questioned why the White House did not answer sooner and said the initial silence raised doubts.
Compassionate use requests are not common for weight-loss drugs. The FDA pathway is meant for emergency cases, not general obesity treatment.
STAT reported that approving it for one patient stands out because retatrutide remains experimental and not yet available to the public.
Also Read: Trump DOJ Withdraws Subpoenas Targeting Washington Post, Wall Street Journal Reporters
Eli Lilly has not commented publicly on the specific case. The company is running large Phase 3 trials for retatrutide.
Positive data has raised hopes that the drug could one day offer even greater weight loss than existing treatments.
Trump’s own history with weight and health has drawn attention over the years. During his first term and the 2024 campaign, he faced questions about his diet and physical condition.
He has not publicly discussed using any GLP-1 drugs like those in the current obesity boom.
Why Weight-Loss Drugs Remain a Major Political and Public Health Topic
Weight-loss injections remain a hot topic in Washington and across the nation. The Trump administration has previously worked on deals to expand access and lower prices for approved drugs in the class.
Trump has talked about tackling high drug costs, including for popular treatments from Lilly and Novo Nordisk.
